BACK Novartis builds case for MS drug ofatumumab as FDA decision looms
Click HERE to Subscribe for the MS Beacon Newsletter May 27, 2020 Novartis has reported new data with its multiple…
Ofatumumab Increases NEDA-3 ( no evidence of disease activity) Likelihood in MS, Compared With Teriflunomide
Novartis’s anti-CD20 monoclonal antibody has been shown to increase the odds of patients with multiple sclerosis achieving no evidence of…
Stuart Schlossman
Amid the COVID-19 Pandemic, Neurologists in Canada Report Pulling Back from EMD Serono’s Mavenclad and Sanofi Genzyme’s Lemtrada, While Roche’s Ocrevus Stalls, According to Spherix Global Insights
COVID-19 is unprecedented and rapidly changing situation. Get the latest public health information from CDC: https://www.coronavirus.gov Stay Healthy, Stay Home…
Stuart Schlossman
Long-Term Data Show Sustained Benefit of Siponimod (Mayzent) for Secondary Progressive MS
Click HERE to Subscribe for the MS Beacon Newsletter Jennifer Barrett April 22, 2020 Siponimod (Mayzent, Novartis) had a sustained…
Stuart Schlossman
Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta
COVID-19 is unprecedented and rapidly changing situation. Get the latest public health information from CDC: https://www.coronavirus.gov Stay Healthy, Stay Home…
Stuart Schlossman
Having MS does not make you Immune Compromised — The Use however of certain Disease Modifying Therapies (DMT’s), Can or Will make you Immunocomprised..
COVID-19 is unprecedented and a rapidly changing situation. Get the latest public health information from CDC: https://www.coronavirus.gov Stay Healthy, Stay…
Stuart Schlossman
Disease-modifying Treatments and Cognition in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis
Click HERE to Subscribe for the MS Beacon Newsletter Full report Abstract Objective: Disease-modifying treatments (DMTs) are the gold standard for…
Stuart Schlossman
FDA Approves Bafiertam, (a Tecfidera) Generic, for Relapsing MS
Banner Life Sciences Announces Final FDA Approval of BAFIERTAM for Multiple Sclerosis BAFIERTAM™ (monomethyl fumarate), the bioequivalent alternative to Biogen’s…
Stuart Schlossman
Siponimod Shows EDSS Subscale Benefits in Secondary Progressive MS
Novartis’s S1P receptor modulator siponimod (Mayzent) showed benefits in a number of patients with SPMS on the Motor Integration and…
Stuart Schlossman
The COVID-19 pandemic and the use of MS disease-modifying therapies
Maria was distraught after reading about the ‘potential’ epidemic, yet to happen, and the horror stories on Facebook needing reassurance…
Stuart Schlossman
